Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talha Badar

Showing results (41-50 of 113) with videos related to

Pageof 12
Sort By:
Blood Advances|January 4, 2020
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCTTalha Badar, Narendranath Epperla, Aniko Szabo, et al.
American Journal of Hematology|May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcomeTalha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
European Journal of Haematology|January 17, 2016
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvementTalha Badar, Amanda Megan Cornelison, Nina D Shah, et al.
Transplantation and Cellular Therapy|July 5, 2023
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid LeukemiaMuhammad Bilal Abid, Noel Estrada-Merly, Mei-Jie Zhang, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Ejhaem|August 19, 2024
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemiaAlexandra E Rojek, Benjamin J McCormick, Joanna Cwykiel, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
Haematologica|May 14, 2026
<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patientsAbiola B Bolarinwa, Natasha Szuber, Janick Caron-Lecuyer, et al.
Haematologica|July 24, 2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Samuel J Yates, Julian J Weiss, Abigail Sneider, et al.
Blood Cancer Journal|September 22, 2023
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneityTalha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, et al.
Pageof 12

Showing results (41-50 of 113) with videos related to

Sort By:
Pageof 12
Blood Advances|January 4, 2020
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCTTalha Badar, Narendranath Epperla, Aniko Szabo, et al.
American Journal of Hematology|May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcomeTalha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
European Journal of Haematology|January 17, 2016
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvementTalha Badar, Amanda Megan Cornelison, Nina D Shah, et al.
Transplantation and Cellular Therapy|July 5, 2023
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid LeukemiaMuhammad Bilal Abid, Noel Estrada-Merly, Mei-Jie Zhang, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Ejhaem|August 19, 2024
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemiaAlexandra E Rojek, Benjamin J McCormick, Joanna Cwykiel, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
Haematologica|May 14, 2026
<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patientsAbiola B Bolarinwa, Natasha Szuber, Janick Caron-Lecuyer, et al.
Haematologica|July 24, 2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Samuel J Yates, Julian J Weiss, Abigail Sneider, et al.
Blood Cancer Journal|September 22, 2023
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneityTalha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, et al.
Pageof 12